Here are 1-3 brief analogies for Entrada Therapeutics:

1. Like Moderna built a powerful platform for mRNA delivery, Entrada Therapeutics is developing a "special delivery vehicle" (EEV) platform to get various therapeutics (like oligonucleotides and enzymes) *inside* cells more effectively for severe neuromuscular diseases.
2. Imagine a company like Sarepta Therapeutics, a leader in Duchenne muscular dystrophy treatments, but Entrada is developing next-generation therapies for DMD and other muscle diseases by enhancing drug delivery directly *into* affected cells.
3. Similar to how Alnylam Pharmaceuticals developed innovative ways to deliver RNAi therapies, Entrada is creating a universal "endosomal escape vehicle" platform to deliver various types of drugs more effectively *inside* cells, unlocking new treatments for difficult diseases.

• ENTR-601-44: A lead product candidate in preclinical trials for the treatment of Duchenne muscular dystrophy and myotonic dystrophy type 1.
• EEV-PMO-CAG: A therapeutic candidate in development for the treatment of myotonic dystrophy type 1.

Entrada Therapeutics (TRDA) is a biotechnology company focused on the development of therapeutics for multiple neuromuscular diseases. The company's lead product candidates, ENTR-601-44 and EEV-PMO-CAG, are currently in preclinical trials.

As Entrada Therapeutics is in the preclinical stage of drug development, it does not currently have any commercial products approved for sale on the market. Consequently, the company does not have major customers in the traditional sense of selling products or services to individuals or other companies at this time. Its operations are focused on research and development.

Dipal Doshi, Chief Executive Officer and Director

Dipal Doshi has served as Chief Executive Officer of Entrada Therapeutics since August 2017. He previously held the position of Chief Business Officer at Amicus Therapeutics, a global biotechnology company focused on rare diseases. Earlier in his career, he gained experience in investment banking at Merrill Lynch and held various roles at Eli Lilly and Company. Doshi also held senior-level positions at a healthcare private equity fund. He was involved with Catalent, which was acquired by Novo Holdings. He currently serves on the Board of Directors of Azenta Life Sciences and āshibio, a privately held, clinical-stage biotechnology company.

Kory Wentworth, CPA, Chief Financial Officer and Treasurer

Kory Wentworth joined Entrada Therapeutics in 2020. As Chief Financial Officer and Treasurer, he oversees finance, business services, and information technology. Prior to Entrada, he was Vice President, Finance and Treasurer, and Principal Accounting Officer at bluebird bio, where he was responsible for building a global finance team to support operational expansion, commercial product launches, equity financing, and strategic collaborations. For nine years before bluebird bio, Wentworth held positions of increasing responsibility at Alexion Pharmaceuticals, most recently as Executive Director and Corporate Controller. He began his career at PricewaterhouseCoopers LLP, where he spent six years in audit engagements.

Nathan J. Dowden, President and Chief Operating Officer

Nathan J. Dowden is the President and Chief Operating Officer of Entrada Therapeutics, a role he assumed in 2024 after joining the company as Chief Operating Officer in 2019. He is responsible for strategic planning, business development, portfolio management, and general operations. Dowden brings nearly 30 years of strategy, investment, and operational experience in the healthcare sector. His previous roles include Senior Vice President of Strategy and Corporate Development at Rubius Therapeutics. He also served as Managing Director at Huron Consulting Group and spent 16 years leading The Frankel Group, a boutique life sciences strategy consulting firm.

Natarajan Sethuraman, PhD, President of Research and Development

Natarajan Sethuraman joined Entrada Therapeutics as Chief Scientific Officer in 2017 and was promoted to President of Research and Development in 2024. He has deep and broad experience in drug discovery and development across various modalities, including oligonucleotides, antibodies, therapeutic enzymes, and peptides. Before his time at Entrada, Sethuraman spent 10 years at Merck & Co., Inc., where he led the GlycoFi site and was involved in the research and development of novel biologics. He joined Merck following its acquisition of GlycoFi in 2006.

Jared Cohen, PhD, JD, General Counsel

Jared Cohen serves as General Counsel for Entrada Therapeutics. In this role, he leads the company's legal, intellectual property, corporate governance, and compliance functions, and also acts as Corporate Secretary. Cohen joined Entrada in 2020 as Vice President and Head of Intellectual Property and Legal Affairs, and was promoted to General Counsel in 2022.

The key risks to Entrada Therapeutics (TRDA) are primarily associated with its stage of development as a biotechnology company focused on novel drug platforms.

1. Clinical Trial and Regulatory Binary Risk: The most significant risk stems from the inherent uncertainties of clinical-stage biotechnology, particularly the "binary risk" associated with clinical trial outcomes. The company's future and the validation of its Endosomal Escape Vehicle (EEV) platform are heavily dependent on the successful advancement of its therapeutic candidates, such as ENTR-601-44 and VX-670, through clinical trials and regulatory approval processes. Negative or inconclusive results from ongoing Phase 1/2 studies for its lead programs, especially those targeting Duchenne muscular dystrophy and myotonic dystrophy type 1, would severely undermine the entire EEV platform and Entrada's valuation. The company has also faced past challenges, including FDA holds on two Investigational New Drug (IND) applications.

2. Significant Operating Losses and Need for Future Funding: Entrada Therapeutics operates with substantial net losses and a high cash burn rate, which is typical for a clinical-stage biotech company. The company is investing heavily in its early-stage pipeline, leading to increased operating expenses and a significant decline in collaboration revenue compared to previous years. While Entrada currently holds a robust cash position expected to fund operations into the second quarter of 2027, it will likely require additional capital to sustain ongoing research and development efforts and advance its programs toward commercialization. Analysts anticipate the company will remain unprofitable for the next three years.

3. Unvalidated Platform Technology: Entrada's proprietary Endosomal Escape Vehicle (EEV) platform, which is foundational to its pipeline, has not yet been fully validated in late-stage human trials. The platform's ability to safely and effectively deliver therapeutics to intracellular targets, a mechanism central to its value proposition, has not been confirmed in the large patient populations and long-term safety studies required for commercial approval. The success of its lead programs is critical for demonstrating the efficacy and safety of the EEV technology in a broader clinical context.

The addressable markets for Entrada Therapeutics' main products are as follows:

• Duchenne Muscular Dystrophy (DMD) (for ENTR-601-44):
  • The global Duchenne Muscular Dystrophy market size is projected to reach approximately USD 7,409.32 million by 2031, growing from USD 3,351.6 million in 2024.
  • Across the seven major markets (7MM), which include the U.S., France, Germany, Italy, Spain, the U.K., and Japan, sales are projected to increase from USD 2.3 billion in 2023 to USD 5.2 billion by 2033.
• Myotonic Dystrophy Type 1 (DM1) (for EEV-PMO-CAG):
  • The global myotonic dystrophy treatment market is anticipated to reach approximately USD 2,789.35 million by 2033.
  • Across the top 7 markets (U.S., EU4, U.K., and Japan), the myotonic dystrophy market reached a value of USD 105.6 million in 2024 and is expected to reach USD 295.2 million by 2035.

Entrada Therapeutics (TRDA) is a biotechnology company focused on developing endosomal escape vehicle (EEV) therapeutics for various neuromuscular and ocular diseases. The company's future revenue growth over the next 2-3 years is anticipated to be driven by the advancement of its robust clinical pipeline and strategic partnerships.

Drivers of Future Revenue Growth:

1. Progression and Positive Data Readouts from the Duchenne Muscular Dystrophy (DMD) Pipeline: Entrada Therapeutics is heavily investing in its DMD franchise, with multiple exon-skipping candidates (ENTR-601-44, ENTR-601-45, ENTR-601-50, and ENTR-601-51) poised for significant clinical milestones. The company expects a "data-rich year" in 2026, with data from the first cohort of the ENTR-601-44 Phase 1/2 study anticipated in Q2 2026, and data from ENTR-601-45 in mid-2026. Additionally, regulatory applications for ENTR-601-50 in the EU are planned for the second half of 2026, with study initiation by year-end, and global regulatory submissions for ENTR-601-51 are also expected in 2026. Successful advancement through these clinical stages and positive trial results could pave the way for regulatory approvals and subsequent commercialization, forming a significant long-term revenue stream.
2. Achievement of Development and Regulatory Milestones from the Myotonic Dystrophy Type 1 (DM1) Partnership with Vertex (VX-670): Entrada has a strategic collaboration with Vertex Pharmaceuticals for the development of VX-670 (formerly ENTR-701) for myotonic dystrophy type 1. While the initial collaboration research income is winding down, future revenue from this partnership is contingent upon the achievement of development, regulatory, and commercial milestones, as well as tiered royalties on future net sales. The completion of enrollment and dosing for the Multiple Ascending Dose (MAD) portion of the VX-670 global Phase 1/2 study, expected in the first half of 2026, represents a critical catalyst for potential milestone payments.
3. Expansion into Ocular Diseases with Novel Clinical Candidates: Entrada is strategically expanding its pipeline into new therapeutic areas, including ocular diseases. The company has selected ENTR-801 as its first clinical candidate for Usher syndrome type 2A, an inherited retinal disorder, and anticipates nominating a second ocular disease candidate later in 2026. Successful preclinical and clinical development in these new areas could diversify Entrada's therapeutic portfolio and create additional avenues for future revenue generation beyond its current focus on neuromuscular conditions.

Share Issuance

• Entrada Therapeutics completed a $116 million Series B financing round in March 2021.
• The company executed a $100 million registered direct offering in June 2024 to bolster its balance sheet.
• As of Q4 2025, Entrada Therapeutics had 38 million shares outstanding, an increase of 0.2% from the prior quarter.

Inbound Investments

• Entrada Therapeutics secured $116 million in a Series B financing round in March 2021, led by Wellington Management Company, with participation from Redmile Group, TCG Crossover, and Goldman Sachs, among others.
• The company entered into a strategic collaboration and license agreement with Vertex Pharmaceuticals Incorporated, receiving an upfront payment of $223.7 million and potentially up to $485.0 million in milestone payments, effective December 2022.
• In October 2023, Entrada achieved a milestone in its collaboration with Vertex Pharmaceuticals, triggering a $17.5 million payment.

Capital Expenditures

• Capital expenditures for Entrada Therapeutics were approximately -$1.04 million in the last 12 months as of March 2026.
• In Q4 2025, the company's capital expenditures were -$207K, representing a 21.1% decrease from the previous quarter.